Navigation Links
Long-Term Mesothelioma Patient and Caregiver Couple Honored as 'Volunteer of the Year'
Date:3/30/2009

SANTA BARBARA, Calif., March 30 /PRNewswire-USNewswire/ -- One of the longest-term survivors of the vicious asbestos-related cancer, mesothelioma, and his wife were honored today by the Mesothelioma Applied Research Foundation with the Foundation's annual Volunteer of the Year Award.

In July of 1998, in St. Charles, Missouri, then-42 year-old Craig Kozicki walked into his doctor's office with concern over a few digestive symptoms. Nine days later, he walked out of the doctor's office, having been told to get his affairs in order because he had only a few months left to live.

But instead of going home and preparing to die, Craig - with his wife Shelly - found their way to one of the few cancer centers at the time attempting to treat the disease. Over the next eleven years, Craig pushed the boundaries of mesothelioma treatment through experimental surgeries, chemotherapy cocktails and radiation. Contrary to the hopeless prognosis he was given, he was able to continue working, be a life partner to Shelly, and see his daughter grow up. Last December, Craig walked Emily - who was just 12 when he was diagnosed and is now 23, down the aisle.

Craig and Shelly also became pioneering advocates for other mesothelioma patients. They joined the Meso Foundation and used Craig's story as a long term survivor effectively treated by multi-modal therapy to inspire countless other patients to keep hope and pursue the latest treatments. One of these patients is Mary Jane Williams of Springfield, Ohio. After she was diagnosed in 2004 and told - just like Craig - to get her affairs in order because there was nothing that could be done, she found the Meso Foundation and then Craig. His refusal to take "no" for an answer gave Mary Jane the hope she needed to get through her protocols. She speaks for many when she says, "If it were not for Craig, I would not be alive today."

While Craig was fighting his battle th
'/>"/>

SOURCE Mesothelioma Applied Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Smoking may strongly increase long-term risk of eye disease
2. Long-Term Fatigue Plagues Cancer Survivors
3. Dont Ignore Tough or Long-Term Stomach Pain
4. Shaking may cause brain damage and serious long-term effects to infants
5. Sexual function affected by stem cell transplant according to long-term study
6. Smoking can harm the long-term effects of some oral surgery procedures
7. Childhood Obesity Epidemic a Long-Term Challenge
8. Conseco to Host Follow-Up Long-Term Care Conference Call
9. New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care
10. No Link Between Amateur Boxing, Long-Term Brain Damage
11. No strong evidence linking amateur boxing with long-term brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Hear Indiana Announces Talk*Walk*Run 2008 2Health News:Hear Indiana Announces Talk*Walk*Run 2008 3Health News:USDA Grants Organic Certification to Ayala's Herbal Water(TM) 2Health News:Prevention and control of childhood pneumonia: Bulletin of the World Health Organization 2Health News:Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting 2Health News:Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting 3Health News:AVEENO(R) Announces Sponsorship and Kick-Off of The Skin Cancer Foundation's 'Road to Healthy Skin Tour' Presented by AVEENO(R) and Rite Aid 2Health News:AVEENO(R) Announces Sponsorship and Kick-Off of The Skin Cancer Foundation's 'Road to Healthy Skin Tour' Presented by AVEENO(R) and Rite Aid 3Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 2Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 3
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 1Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 2Menopause Is More Than A Hot Flash 51759 1Menopause Is More Than A Hot Flash 51759 2Menopause Is More Than A Hot Flash 51759 3Menopause Is More Than A Hot Flash 51759 4Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 1Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 2Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 3